PMID- 9924695
OWN - NLM
STAT- MEDLINE
DCOM- 19990325
LR  - 20201222
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 22
IP  - 1
DP  - 1999 Jan
TI  - Prolonged upregulation of the expression of HLA class I antigens and 
      costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine 
      (5-AZA-CdR).
PG  - 16-24
AB  - The immunogenic potential of melanoma cells and their recognition by the host's 
      cytotoxic cells depends on the presence and on the level of expression of human 
      leukocyte antigen (HLA) class I antigens, costimulatory molecules and 
      melanoma-associated antigens (MAA), on neoplastic cells. In this study, we 
      demonstrate that the DNA hypomethylating agent 5-aza-2'-deoxycytidine 
      (5-AZA-CdR), significantly (p < 0.05) enhanced the constitutive expression of HLA 
      class I antigens, HLA-A1 and -A2 alleles, and of the costimulatory molecules 
      intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3, 
      on a panel of 12 melanoma cells. This upregulation peaked at day 4, slowly 
      decreased thereafter, and returned to baseline levels 32 days after the end of 
      treatment. In addition, treatment with 5-AZA-CdR induced a persistent expression 
      of MAGE-1 in Mel 275 melanoma cells; this was still detectable, by reverse 
      transcriptase polymerase chain reaction, 60 days after the end of treatment. In 
      contrast, 5-AZA-CdR did not affect the constitutive expression of the high 
      molecular weight-MAA by the melanoma cells investigated. These observations, 
      together with data obtained comparing the effect of 5-AZA-CdR with that of 
      interferon-gamma, strongly suggest that 5-AZA-CdR may have prospective 
      therapeutic implications in active and/or passive specific immunotherapy for 
      human melanoma.
FAU - Coral, S
AU  - Coral S
AD  - Advanced Immunotherapy Unit, Istituto Nazionale di Ricovero e Cura a Carattere 
      Scientifico, Aviano, Italy.
FAU - Sigalotti, L
AU  - Sigalotti L
FAU - Gasparollo, A
AU  - Gasparollo A
FAU - Cattarossi, I
AU  - Cattarossi I
FAU - Visintin, A
AU  - Visintin A
FAU - Cattelan, A
AU  - Cattelan A
FAU - Altomonte, M
AU  - Altomonte M
FAU - Maio, M
AU  - Maio M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (CD58 Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (MAGEA1 protein, human)
RN  - 0 (Melanoma-Specific Antigens)
RN  - 0 (Neoplasm Proteins)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
SB  - IM
MH  - Alleles
MH  - Antigens, Neoplasm
MH  - Azacitidine/*analogs & derivatives/pharmacology
MH  - Blotting, Western
MH  - CD58 Antigens/*biosynthesis
MH  - Decitabine
MH  - Flow Cytometry
MH  - Histocompatibility Antigens Class I/*biosynthesis/genetics
MH  - Humans
MH  - Intercellular Adhesion Molecule-1/*biosynthesis
MH  - Melanoma/*immunology
MH  - Melanoma-Specific Antigens
MH  - Neoplasm Proteins/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Time Factors
MH  - Tumor Cells, Cultured
MH  - Up-Regulation/drug effects
EDAT- 1999/01/30 00:00
MHDA- 1999/01/30 00:01
CRDT- 1999/01/30 00:00
PHST- 1999/01/30 00:00 [pubmed]
PHST- 1999/01/30 00:01 [medline]
PHST- 1999/01/30 00:00 [entrez]
AID - 10.1097/00002371-199901000-00003 [doi]
PST - ppublish
SO  - J Immunother. 1999 Jan;22(1):16-24. doi: 10.1097/00002371-199901000-00003.